SI2331210T1 - Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika - Google Patents

Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika

Info

Publication number
SI2331210T1
SI2331210T1 SI200931014T SI200931014T SI2331210T1 SI 2331210 T1 SI2331210 T1 SI 2331210T1 SI 200931014 T SI200931014 T SI 200931014T SI 200931014 T SI200931014 T SI 200931014T SI 2331210 T1 SI2331210 T1 SI 2331210T1
Authority
SI
Slovenia
Prior art keywords
antiepileptic
dimethylamino
phenol
propyl
ethyl
Prior art date
Application number
SI200931014T
Other languages
English (en)
Slovenian (sl)
Inventor
Petra Bloms-Funke
Klaus Schiene
Thomas Christoph
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2331210(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of SI2331210T1 publication Critical patent/SI2331210T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI200931014T 2008-09-05 2009-09-04 Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika SI2331210T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05
EP09778335.1A EP2331210B1 (en) 2008-09-05 2009-09-04 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
PCT/EP2009/006424 WO2010025931A2 (en) 2008-09-05 2009-09-04 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SI2331210T1 true SI2331210T1 (sl) 2014-10-30

Family

ID=40345058

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200931014T SI2331210T1 (sl) 2008-09-05 2009-09-04 Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
SI200931945T SI2735338T1 (sl) 2008-09-05 2009-09-04 Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200931945T SI2735338T1 (sl) 2008-09-05 2009-09-04 Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina

Country Status (28)

Country Link
US (1) US20100063148A1 (enExample)
EP (2) EP2735338B1 (enExample)
JP (4) JP5731387B2 (enExample)
KR (3) KR101641519B1 (enExample)
CN (2) CN105520924B (enExample)
AR (2) AR073361A1 (enExample)
AU (3) AU2009289776A1 (enExample)
BR (1) BRPI0920521A2 (enExample)
CA (1) CA2735857C (enExample)
CL (1) CL2011000317A1 (enExample)
CO (1) CO6382142A2 (enExample)
CY (2) CY1115751T1 (enExample)
DK (2) DK2735338T3 (enExample)
EC (1) ECSP11010869A (enExample)
ES (2) ES2719900T3 (enExample)
HR (2) HRP20140663T1 (enExample)
HU (1) HUE043278T2 (enExample)
IL (3) IL211135A (enExample)
LT (1) LT2735338T (enExample)
MX (1) MX2011002339A (enExample)
PE (5) PE20142372A1 (enExample)
PL (2) PL2331210T3 (enExample)
PT (2) PT2735338T (enExample)
RU (2) RU2674150C1 (enExample)
SI (2) SI2331210T1 (enExample)
TR (1) TR201904388T4 (enExample)
WO (1) WO2010025931A2 (enExample)
ZA (1) ZA201101449B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
KR20150003925A (ko) 2006-06-15 2015-01-09 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101641519B1 (ko) * 2008-09-05 2016-07-21 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
WO2011157391A1 (en) * 2010-06-15 2011-12-22 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US20120009261A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
BR112013000164B1 (pt) 2010-07-30 2021-11-23 Toray Industries, Inc Agente terapêutico ou agente profilático
AU2012224953C1 (en) * 2011-03-04 2017-07-13 Grünenthal GmbH Parenteral administration of tapentadol
WO2013011477A1 (en) * 2011-07-20 2013-01-24 Torrent Pharmaceuticals Ltd Pharmaceutical invention of tapentadol
RS56947B1 (sr) * 2011-07-29 2018-05-31 Gruenenthal Gmbh Intratekalno ili epiduralno davanje 3-[(1s,2s)-3-(dimetilamino)-1-etil-2-metilpropil]fenola
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
WO2014068372A1 (en) * 2012-11-01 2014-05-08 Torrent Pharmaceuticals Ltd Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
PL4293009T3 (pl) 2015-12-22 2025-10-06 Zogenix International Limited Kompozycje fenfluraminy i sposoby ich wytwarzania
IL290727B2 (en) 2016-08-24 2023-12-01 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
CA3117868A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
SK286621B6 (sk) * 1999-08-20 2009-02-05 Ortho-Mcneil Pharmaceutical, Inc. Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva
US20060167032A1 (en) * 2002-01-16 2006-07-27 Galer Bradley S Pharmaceutical composition and method for treating disorders of the central nervous system
WO2003070237A1 (en) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
ES2358763T3 (es) * 2006-04-28 2011-05-13 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
EP2219633A2 (en) * 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
JP5563483B2 (ja) * 2008-01-25 2014-07-30 ゼノポート，インコーポレイティド アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
KR101641519B1 (ko) * 2008-09-05 2016-07-21 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물

Also Published As

Publication number Publication date
PL2331210T3 (pl) 2014-12-31
EP2331210B1 (en) 2014-07-09
HK1159011A1 (en) 2012-07-27
ECSP11010869A (es) 2011-04-29
EP2735338B1 (en) 2019-02-06
RU2571501C2 (ru) 2015-12-20
PE20142371A1 (es) 2015-02-04
AU2016203053A1 (en) 2016-06-02
CY1115751T1 (el) 2017-01-25
CA2735857A1 (en) 2010-03-11
IL211135A (en) 2017-09-28
PT2331210E (pt) 2014-08-25
PT2735338T (pt) 2019-05-24
KR101730924B1 (ko) 2017-04-27
CN105520924A (zh) 2016-04-27
AR073361A1 (es) 2010-11-03
US20100063148A1 (en) 2010-03-11
KR20110057144A (ko) 2011-05-31
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
IL237392A0 (en) 2015-04-30
CN102159284A (zh) 2011-08-17
HRP20190500T1 (hr) 2019-08-09
DK2735338T3 (en) 2019-04-23
CN105520924B (zh) 2019-04-09
WO2010025931A3 (en) 2010-06-17
KR101641519B1 (ko) 2016-07-21
IL237391A (en) 2017-12-31
IL237392B (en) 2019-08-29
AU2018202879A1 (en) 2018-05-17
CO6382142A2 (es) 2012-02-15
ES2719900T3 (es) 2019-07-16
AU2009289776A1 (en) 2010-03-11
RU2674150C1 (ru) 2018-12-05
PE20142372A1 (es) 2015-02-04
JP5731387B2 (ja) 2015-06-10
EP2331210A2 (en) 2011-06-15
IL237391A0 (en) 2015-04-30
PE20190914A1 (es) 2019-06-26
HK1198145A1 (en) 2015-03-13
ZA201101449B (en) 2011-10-26
AR117613A2 (es) 2021-08-18
PE20142357A1 (es) 2015-02-04
AU2018202879B2 (en) 2020-03-12
ES2513394T3 (es) 2014-10-27
CL2011000317A1 (es) 2011-06-17
KR20170048602A (ko) 2017-05-08
JP2019131578A (ja) 2019-08-08
HRP20140663T1 (hr) 2014-10-10
TR201904388T4 (tr) 2019-05-21
PL2735338T3 (pl) 2019-07-31
CY1121492T1 (el) 2020-05-29
AU2016203053B2 (en) 2018-01-25
PE20110291A1 (es) 2011-06-04
CA2735857C (en) 2019-05-28
HUE043278T2 (hu) 2019-08-28
DK2331210T3 (da) 2014-08-11
JP2015096530A (ja) 2015-05-21
IL211135A0 (en) 2011-04-28
CN102159284B (zh) 2015-12-09
JP2017071636A (ja) 2017-04-13
MX2011002339A (es) 2011-04-04
EP2735338A1 (en) 2014-05-28
SI2735338T1 (sl) 2019-04-30
BRPI0920521A2 (pt) 2018-01-16
JP2012501986A (ja) 2012-01-26
KR20160086981A (ko) 2016-07-20
WO2010025931A2 (en) 2010-03-11
RU2011112444A (ru) 2012-10-10

Similar Documents

Publication Publication Date Title
IL237391A (en) Combination of 3 - (3 Dimethylamino - 1 - Ethyl - 2 - Methyl - Profile) - Phenol and Epilepsy
GB2456813B (en) Diagnostic context construction and comparison
IL243015B (en) Polycyclic compounds and pharmaceutical preparations containing them
EP2445340A4 (en) SUBSTITUTED HYDROXAMINE ACIDS AND USES THEREOF
BRPI0909750A2 (pt) dispositivo e cápsula para a preparação de uma bebida
IL211785A0 (en) CO-CRYSTALS OF TRAMADOL AND NSAIDs
IL217774A0 (en) Compositions for treating gaucher disease and uses thereof
IL218016A0 (en) Pharmaceutical compositions comprising bi-1356 and metformin
EP2486918A4 (en) PHARMACEUTICAL COMPOSITION WITH BOTH IMMEDIATE AND DELAYED RELEASE
PT2474522E (pt) Agomelatina e composições farmacêuticas que contêm a mesma
GB201014075D0 (en) Risk and reward assessment mechanism
ZA201200079B (en) Pharmaceutical compositions and solid forms
ZA201201892B (en) Co-crystals of tramadol and coxibs
ZA201102682B (en) Aptamer for agf and use thereof
IL201247A0 (en) Combinations of statins and anti-obesity agent
IL219963A (en) Pharmaceutical composition containing transcorsorcaline hydrochloride and mannitol and its use
EP2322608A4 (en) TRANSFECTION AGENT
EP2232192A4 (en) QUICK AND EASY TO INSTALL CASE
PL2236145T3 (pl) Kompozycja farmaceutyczna i lek złożony
ZA201100529B (en) Solid pharmaceutical composition comprising exemestane
PL2488169T3 (pl) Kokryształy tramadolu i koksybów
HK1155261A (en) Risk and reward assessment mechanism
GB0901964D0 (en) Co-crystals and their use
PL389370A1 (pl) Substancja stała o właściwościach bakterio- i grzybobójczych
GB0916142D0 (en) Tendon vascularity analyser